Influence of sitgliptin and metformin treatment on glucose fluctuation and serum inflammatory factors in preliminary diagnosed type 2 diabetes mellitus

摘要

Objective:To investigate the influence of stigliptin and metformin treatment on glucose fluctuation and serum inflammatory factors in preliminary diagnosed Type 2 diabetes mellitus. Methods: From January 2014 to December 2015, 168 cases of patients with newly diagnosed Type 2 diabetes mellitus were recruited and divided randomly into observation group and control group. The observation group was given sitgliptin (Januvia, 100 mg per d), while the control group was given metformin (Glucophage tablet, initial dose 0.5 g bid, twice per d), and the dosage of drugs was adjusted every 2 weeks according to glucose level. If the glucose level still wasn’t controlled to reach the normal standard by maximum dosage of drugs, 0.5 g bid of acarbose (Glucobay) was applied for the treatment 3 times one day till the glucose level reached the normal standard and the observation was kept for 6 months. The HbA1c, BMI, fluctuation indexes, and serum inflammatory factors of two groups were compared. Results: After the treatment of control group and observation group, the differences of PPGE (t=8.425,P=0.012), MAGE (t=7.348,P=0.014) and MODD (t=9.327,P=0.010) between two groups were significant (P<0.05). The differences of IL-6 (t=6.337,P=0.010) and TNF-α(t=6.521,P=0.011) level of observation group and control group after treatment were statistical significant (P<0.05).Conclusions:The sitgliptin could not only achieve glycemic control goal as metformin, but also induce glucose fluctuation and inhibit serum inflammation better.